ConductScience.org, home

Paper41789650

Targeting poly(ADP-ribose) polymerase in metastatic prostate cancer: current landscape and future directions.

Shi X and 3 others. Curr Opin Oncol, 2026. Cited by 0 papers, by iCite.

Cite this record

ConductScience Library. Targeting poly(ADP-ribose) polymerase in metastatic prostate cancer: current landscape and future directions. Papers, record 41789650. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41789650

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Targeting poly(ADP-ribose) polymerase in metastatic prostate cancer: current landscape and future directions.
PubMed
Journal
Curr Opin Oncol
PubMed
Year
2026
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
0
iCite
Revised in PubMed
2026-09-21
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Shi XXiaolei
2Rifai SSafiullah
3Meher ZZumar
4Hussain AArif

Source PubMed

Download CSV of authors

Topics6

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Poly(ADP-ribose) Polymerase InhibitorsMajor topic
Prostatic Neoplasms, Castration-ResistantMajor topic
Prostatic NeoplasmsMajor topic
Humans
Male
Neoplasm Metastasis

Grants2

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
P30 CA134274NCI NIH HHSUnited StatesP30CA134274PubMedNIH RePORTER
T32 CA154274NCI NIH HHSUnited StatesT32CA154274PubMedNIH RePORTER

Download CSV of grants

References49

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
132955174Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer.N Engl J Med2020https://conductscience.org/library/papers/32955174PubMed
237963304Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in BRCA1 and/or BRCA2 in the PROfound Trial.J Clin Oncol2024https://conductscience.org/library/papers/37963304PubMed
335279473Cracking the homologous recombination deficiency code: how to identify responders to PARP inhibitors.Eur J Cancer2022https://conductscience.org/library/papers/35279473PubMed
440683287
Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial.
Lancet2025https://conductscience.org/library/papers/40683287PubMed
540086424Deciphering the mechanisms of PARP inhibitor resistance in prostate cancer: Implications for precision medicine.Biomed Pharmacother2025https://conductscience.org/library/papers/40086424PubMed
628811666The essential kinase ATR: ensuring faithful duplication of a challenging genome.Nat Rev Mol Cell Biol2017https://conductscience.org/library/papers/28811666PubMed
731659317Uncoupling of PARP1 trapping and inhibition using selective PARP1 degradation.Nat Chem Biol2019https://conductscience.org/library/papers/31659317PubMed
821383736Targeting the missing links for cancer therapy.Nat Med2011https://conductscience.org/library/papers/21383736PubMed
930345412Homology-Directed Repair and the Role of BRCA1, BRCA2, and Related Proteins in Genome Integrity and Cancer.Annu Rev Cancer Biol2018https://conductscience.org/library/papers/30345412PubMed
1037290035Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial.J Clin Oncol2023https://conductscience.org/library/papers/37290035PubMed
1138319800Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer.NEJM Evid2022https://conductscience.org/library/papers/38319800PubMed
1240582078Expanding PARP Inhibitor Use in Prostate Cancer Beyond DNA Repair Defects.Clin Oncol (R Coll Radiol)2025https://conductscience.org/library/papers/40582078PubMed
1332123273Androgen Receptor and Poly(ADP-ribose) Glycohydrolase Inhibition Increases Efficiency of Androgen Ablation in Prostate Cancer Cells.Sci Rep2020https://conductscience.org/library/papers/32123273PubMed
1437882449TALAPRO-3 clinical trial protocol: phase III study of talazoparib plus enzalutamide in metastatic castration-sensitive prostate cancer.Future Oncol2024https://conductscience.org/library/papers/37882449PubMed
1539848867Heterogeneity of the Treatment Effect with PARP Inhibitors in Metastatic Castration-resistant Prostate Cancer: A Living Interactive Systematic Review and Meta-analysis.Eur Urol2025https://conductscience.org/library/papers/39848867PubMed
1612933815Role of XRCC1 in the coordination and stimulation of oxidative DNA damage repair initiated by the DNA glycosylase hOGG1.J Biol Chem2003https://conductscience.org/library/papers/12933815PubMed
1737126020Metastatic Prostate Cancers with BRCA2 versus ATM Mutations Exhibit Divergent Molecular Features and Clinical Outcomes.Clin Cancer Res2023https://conductscience.org/library/papers/37126020PubMed
1828851861Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer.Nat Commun2017https://conductscience.org/library/papers/28851861PubMed
1936650183CRISPR screens reveal genetic determinants of PARP inhibitor sensitivity and resistance in prostate cancer.Nat Commun2023https://conductscience.org/library/papers/36650183PubMed
2036361678PTEN Loss Enhances Error-Prone DSB Processing and Tumor Cell Radiosensitivity by Suppressing RAD51 Expression and Homologous Recombination.Int J Mol Sci2022https://conductscience.org/library/papers/36361678PubMed

See all 49 referencesDownload CSV of references

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
BRCA1672PubTator's text mininghttps://conductscience.org/library/genes/672NCBI Gene
PARP1142PubTator's text mininghttps://conductscience.org/library/genes/142NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Cited by
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41789650

GET https://conductscience.org/api/papers/v1/41789650/references?page=2